Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Get Free Report) has earned a consensus rating of “Moderate Buy” from the fourteen research firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have given a buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $46.08.
TEVA has been the topic of a number of recent analyst reports. Piper Sandler lifted their price objective on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 28th. Barclays raised their target price on Teva Pharmaceutical Industries from $42.00 to $47.00 and gave the company an “overweight” rating in a report on Thursday, October 15th. Leerink Partners began coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, September 9th. They issued an “outperform” rating and a $45.00 price objective on the stock. Zacks Research downgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 20th. Finally, Wall Street Zen lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th.
Teva Pharmaceutical Industries Price Performance
NYSE TEVA opened at $42.07 on Friday. The company has a market cap of $49.02 billion, a P/E ratio of 70.12, a P/E/G ratio of 3.90 and a beta of 0.89. The company has a current ratio of 0.88, a quick ratio of 0.67 and a debt-to-equity ratio of 1.56. Teva Pharmaceutical Industries has a 1 year low of $19.98 and a 1 year high of $42.59. The company has a fifty day simple moving average of $39.07 and a 200 day simple moving average of $34.55.
Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last released its quarterly earnings results on Tuesday, June 30th. The company reported $0.02 earnings per share (EPS) for the quarter. The company had revenue of $4.14 billion during the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. On average, sell-side analysts predict that Teva Pharmaceutical Industries will post 2.00 EPS for the current year.
Insider Transactions at Teva Pharmaceutical Industries
In related news, Director Roberto Mignone sold 367,600 shares of Teva Pharmaceutical Industries stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $39.06, for a total transaction of $14,358,456.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Brian Savage sold 7,342 shares of Teva Pharmaceutical Industries stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $38.85, for a total value of $285,236.70. Following the sale, the insider directly owned 8,500 shares in the company, valued at approximately $330,225. This trade represents a 46.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 374,959 shares of company stock valued at $14,644,285 in the last ninety days. 0.54% of the stock is owned by company insiders.
Hedge Funds Weigh In On Teva Pharmaceutical Industries
Several large investors have recently added to or reduced their stakes in TEVA. Cornerstone Planning Group LLC boosted its stake in shares of Teva Pharmaceutical Industries by 547.1% in the 1st quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock valued at $27,000 after purchasing an additional 755 shares in the last quarter. Root Financial Partners LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth about $33,000. Western Wealth Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the 1st quarter worth about $43,000. Sunbelt Securities Inc. acquired a new stake in shares of Teva Pharmaceutical Industries during the 1st quarter worth about $45,000. Finally, EverSource Wealth Advisors LLC lifted its holdings in Teva Pharmaceutical Industries by 64.0% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,658 shares of the company’s stock valued at $50,000 after purchasing an additional 647 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. Founded in 1901, the company is one of the world’s largest producers of generic medicines and develops, manufactures and distributes prescription products across a broad range of therapeutic areas.
Teva’s portfolio includes generic medicines, specialty pharmaceuticals, biosimilars, active pharmaceutical ingredients and over-the-counter products. Its specialty medicines include treatments for neurological and movement disorders, respiratory conditions, migraine and other chronic diseases.
Featured Stories
- Five stocks we like better than Teva Pharmaceutical Industries
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.
